Bevacizumab is a recombinant, humanized anti–vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis.
It has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan, fluourouracil, or leucovorin.
Only 3 randomized clinical studies have evaluated bevacizumab in combination with fluourouracil or leucovorin alone.
Dr Somnath Sarkar and colleagues performed a combined analysis of raw data from these studies to better assess the efficacy of bevacizumab with fluourouracil/leucovorin.
The researchers used primary efficacy data from 3 independent studies.
The analyzed studies included 241 patients in a combined control group receiving either fluourouracil/leucovorin or irinotecan.
| Progression-free survival was 9 months with combined treatment versus 6 in the controls|
|Journal of Clinical Oncology|
The team also analyzed 249 patients receiving fluourouracil/leucovorin/bevacizumab of 5 mg/kg once every 2 weeks.
The research team reported that the efficacy data included response rate, progression-free survival, and overall survival.
The team found that the median duration of survival was 18 months in the fluourouracil/leucovorin/bevacizumab group, with 15 months in the control group.
The median duration of progression-free survival was 9 months in the fluourouracil/leucovorin/bevacizumab group, and 6 months in the control group.
The researchers observed that the addition of bevacizumab also improved the response rate.
Dr Sarkar's team concludes, “The addition of bevacizumab to fluourouracil/leucovorin provides a statistically significant and clinically relevant benefit to patients with previously untreated metastatic colorectal cancer.”